ICI-85966: Difference between revisions
CSV import |
CSV import |
||
| Line 31: | Line 31: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:ICI-85966.svg|ICI-85966 | |||
</gallery> | |||
<gallery> | <gallery> | ||
File:ICI-85966.svg|ICI-85966 | File:ICI-85966.svg|ICI-85966 | ||
</gallery> | </gallery> | ||
Revision as of 01:28, 20 February 2025
ICI-85966 is a drug that was developed by Imperial Chemical Industries (ICI) and is known for its analgesic properties. It is a kappa opioid receptor agonist, which means it binds to and activates the kappa opioid receptors in the brain and spinal cord, leading to pain relief.
History
ICI-85966 was developed by the British company Imperial Chemical Industries in the late 20th century. The company, now known as AstraZeneca, has a long history of developing innovative drugs for a variety of medical conditions.
Mechanism of Action
As a kappa opioid receptor agonist, ICI-85966 works by binding to and activating the kappa opioid receptors in the brain and spinal cord. This activation inhibits the release of substance P, a neurotransmitter involved in pain transmission, thereby reducing the perception of pain.
Clinical Use
While ICI-85966 has demonstrated analgesic properties, its use in clinical practice is limited due to its potential for causing dysphoria, a state of unease or dissatisfaction. This is a common side effect of kappa opioid receptor agonists.
Side Effects
The most common side effect of ICI-85966 is dysphoria. Other potential side effects include sedation, nausea, and vomiting. These side effects are generally dose-dependent and may be more pronounced in individuals who are opioid-naive.
